172 related articles for article (PubMed ID: 8892461)
1. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Lamond JP; Wang M; Kinsella TJ; Boothman DA
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):361-8. PubMed ID: 8892461
[TBL] [Abstract][Full Text] [Related]
2. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors.
Lamond JP; Wang M; Kinsella TJ; Boothman DA
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):369-76. PubMed ID: 8892462
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
4. Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Kim JS; Amorino GP; Pyo H; Cao Q; Choy H
Radiother Oncol; 2002 Jan; 62(1):61-7. PubMed ID: 11830313
[TBL] [Abstract][Full Text] [Related]
5. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
Mattern MR; Hofmann GA; McCabe FL; Johnson RK
Cancer Res; 1991 Nov; 51(21):5813-6. PubMed ID: 1657371
[TBL] [Abstract][Full Text] [Related]
6. Interaction of ionizing radiation with topotecan in two human tumor cell lines.
Marchesini R; Colombo A; Caserini C; Perego P; Supino R; Capranico G; Tronconi M; Zunino F
Int J Cancer; 1996 May; 66(3):342-6. PubMed ID: 8621255
[TBL] [Abstract][Full Text] [Related]
7. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
8. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells.
Boothman DA; Wang M; Schea RA; Burrows HL; Strickfaden S; Owens JK
Int J Radiat Oncol Biol Phys; 1992; 24(5):939-48. PubMed ID: 1332930
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines.
Ng CE; Bussey AM; Raaphorst GP
Int J Radiat Biol; 1994 Jul; 66(1):49-57. PubMed ID: 8027612
[TBL] [Abstract][Full Text] [Related]
11. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
Lamond JP; Mehta MP; Boothman DA
J Neurooncol; 1996 Oct; 30(1):1-6. PubMed ID: 8864997
[TBL] [Abstract][Full Text] [Related]
12. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
13. The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids.
Koosha F; Neshasteh-Riz A; Takavar A; Eyvazzadeh N; Mazaheri Z; Eynali S; Mousavi M
Biochem Biophys Res Commun; 2017 Sep; 491(4):1092-1097. PubMed ID: 28797568
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
15. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Rowinsky EK; Kaufmann SH; Baker SD; Grochow LB; Chen TL; Peereboom D; Bowling MK; Sartorius SE; Ettinger DS; Forastiere AA; Donehower RC
J Clin Oncol; 1996 Dec; 14(12):3074-84. PubMed ID: 8955652
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
[TBL] [Abstract][Full Text] [Related]
17. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo.
Boscia RE; Korbut T; Holden SA; Ara G; Teicher BA
Int J Cancer; 1993 Jan; 53(1):118-23. PubMed ID: 8416195
[TBL] [Abstract][Full Text] [Related]
18. The significance of the sequence of administration of topotecan and etoposide.
Bonner JA; Kozelsky TF
Cancer Chemother Pharmacol; 1996; 39(1-2):109-12. PubMed ID: 8995507
[TBL] [Abstract][Full Text] [Related]
19. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
[TBL] [Abstract][Full Text] [Related]
20. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Ma J; Maliepaard M; Nooter K; Boersma AW; Verweij J; Stoter G; Schellens JH
Cancer Chemother Pharmacol; 1998; 41(4):307-16. PubMed ID: 9488600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
